For people who want longer-term mobility, work capacity, and confidence, the next wave of drugs could shape daily life in ways a scale cannot measure. Scientists are testing combinations and new targets to reduce side effects and preserve lean tissue. Those shifts could affect how doctors design treatment plans and how patients plan rehabilitation, exercise, and nutrition.
If you’re curious about what comes after the GLP-1 era, the linked article walks through an early trial that produced large losses and the scientific questions that follow. Read it to learn how these advances might expand who benefits from treatment, change expectations for recovery, and open paths to more inclusive approaches to health and strength.
The first wave of obesity drugs, which dominate the market, has mainly focused on the gut hormone GLP-1, but drugmakers are now looking for medicines that target other hormones or help preserve muscle mass during fat-loss with their next generation of drugs. The experimental…